Laboratory Detection and Clinical Implication of Oxacillinase-48 like Carbapenemase: The Hidden Threat

Yamuna Devi Bakthavatchalam, Shalini Anandan, Balaji Veeraraghavan

Department of Clinical Microbiology, Christian Medical College, Vellore, Tamil Nadu, India

ABSTRACT

Carbapenemase producing Gram-negative pathogen is of great concern for physician. The challenging aspects are treatment option and infection control. Monitoring of respective carbapenemase resistance mechanism is necessary to prevent the outbreaks. Currently, the rapid emergence of oxacillinase (OXA-48) like is alarming. Increasing frequency of OXA-48 is seen than the classical carbapenemase (KPC, NDM, IMP, and VIM) across the world. The blaOXA-48 gene is commonly identified in Escherichia coli and Klebsiella pneumoniae. The transferrable plasmid of OXA-48 is associated with rapid spread and inter-species dissemination. In general, OXA-48-like enzymes weakly hydrolyze both carbapenem and broad spectrum cephalosporins. Except OXA-163, which effectively hydrolyze cephalosporin. This poor hydrolytic profile obscures the detection of OXA-48-like. It may go undetected in routine diagnosis and complicates the treatment option. Co-production of OXA-48-like with CTX-M-15 and other carbapenemase (NDM, VIM) leads to the emergence of multidrug resistant strains.

Key words: Carbapenemase, noscomial, OXA-48, OXA-48-like

INTRODUCTION

The global spread of carbapenemase-producing Gram-negative pathogens is of special concern in healthcare and community settings. Invasive infection causing carbapenemase producers associated with significant mortality and morbidity. Carbenapenemase confer resistance to most β-lactam antibiotics including carbapenem.[3] Moreover, frequent co-existence of other antibiotic resistant genes complicates the therapy and limits the treatment option.[3] The optimal treatment remains undefined. Accurate detection of carbapenemase producers is essential for infection control and management of antibiotic therapy.[3] The most representative carbapenemase is classified in three classes: Class A (KPC), Class B metallo-β-lactamase (IMP, VIM, and NDM), and Class D oxacillinase (OXA-48).[4]

Certainly, OXA-48 a Class D β-lactamase are being increasingly reported with outbreaks and case reports across the world.[3] Horizontal transfer of mobile genetic elements carrying OXA-48-like gene results in rapid spread.[3] OXA-48-like enzyme weakly hydrolyzes both carbapenem and cephalosporin. Hence, elevated minimum inhibitory concentrations (MIC) to carbapenem and cephalosporin is not noticeable with OXA-48 like.[3] It may go undetected with routine diagnosis. Molecular characterization of OXA-48-like is warranted. Recently, many studies have reported OXA-48-like in Enterobacteraeae, especially in Klebsiella spp. Identification of OXA-48 and its variant with short turnaround time promotes the time to active treatment.

The aim of this review is to summarize the characteristics of OXA-48, including hydrolytic activity, distribution of the world.[3] Horizontal transfer of mobile genetic elements carrying OXA-48-like gene results in rapid spread.[3] OXA-48-like enzyme weakly hydrolyzes both carbapenem and cephalosporin. Hence, elevated minimum inhibitory concentrations (MIC) to carbapenem and cephalosporin is not noticeable with OXA-48 like.[3] It may go undetected with routine diagnosis. Molecular characterization of OXA-48-like is warranted. Recently, many studies have reported OXA-48-like in Enterobacteraeae, especially in Klebsiella spp. Identification of OXA-48 and its variant with short turnaround time promotes the time to active treatment.

Address for correspondence:
Dr. Balaji Veeraraghavan, E-mail: vbalaji@cmcvellore.ac.in

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Bakthavatchalam YD, Anandan S, Veeraraghavan B. Laboratory detection and clinical implication of oxacillinase-48 like carbapenemase: The hidden threat. J Global Infect Dis 2016;8:41-50.
enzyme variants, plasmid-mediated rapid spread with a special reference to challenges in laboratory diagnosis and clinical implication.

**Classification of carbapenemase**

Carbapenemase identified in *Enterobacteriaceae, Pseudomonas aeruginosa* and *Acinetobacter baumannii* are placed in three classes of β-lactamase as Ambler Class A, Class B metallo β-lactamase, and carbapenem hydrolyzing Class D oxacillinase.[8] Carbapenemase are classified into two major types based on the active site of the enzyme as serine carbapenemase (KPC and OXA type β-lactamase) and metallo-β-lactamase (IMP, VIM, and NDM). The spectrum of substrate for carbapenemase activity is varied [Table 1].[8]

In the early 1990s, most of the identified carbapenemase are chromosomally encoded. Plasmid-mediated carbapenemase begins to emerge and creates the threat for rapid spread among Gram-negative pathogens.[9] Class A and Class B metallo-β-lactamase are described with well-defined set of characteristics. Notably, synergy test using the inhibitors of boronic acid derivatives (BA) and dipicolinic acid (DPA)/ethylene diamine tetra acetic acid (EDTA) were available to detect Class A and Class B carbapenemase.[10] However, OXA-48 is difficult to identify due to poor hydrolysis of substrates (carbapenem and cephalosporin). In contrast to other carbapenemase, elevated carbapenem MIC is not noticeable with OXA-48 unless co-produced with other β-lactamases.[11] Additionally, phenotypic method using specific inhibitor for OXA-48 is not currently available.[12] It is of great concern for clonal spread and inter-species dissemination. Hence, a phenotypic method for earlier detection of OXA-48 is essential.

In *Enterobacteriaceae*, the most common carbapenemase producers are KPC, IMP, VIM and NDM. Comparatively OXA-48 and its variants are becoming widely distributed of late and commonly reported in *Enterobacteriaceae*. In contrast, so far only two studies have reported OXA-48 in *A. baumannii* and no single study with *P. aeruginosa*.[14]

**Characteristics of oxacillinase-48**

Carbapenem-hydrolyzing Class D β-lactamases are not inhibited by the inhibitor available in clinical use. This includes clavulanic acid, tazobactam and sulbactam.[15] Of the Class D carbapenemase, OXA-48 is of major concern due to its:

1. Difficulty in detection,
2. Association with treatment failure and 
3. High dissemination rate due to transferable plasmid.

Due to this property of OXA-48, susceptible or low-level resistance to cephalosporin and/or carbapenem is seen. Remarkably, enzyme kinetic analysis shows greater catalytic activity of OXA-48 to imipenem than meropenem.[16] OXA-48-like enzyme variants is plasmid coded and is associated with rapid spread in community settings.[17] Further, OXA-48 is frequently reported in clinically important nosocomial pathogens *E. coli* and *Klebsiella pneumoniae*. The high level of OXA-48 resistance is associated with co-production of extended spectrum β-lactamase(ESBL).[18]

**Variants of oxacillinase-48 like enzymes**

A multi-drug resistant *K. pneumoniae* was isolated from a patient in Istanbul, Turkey and found a new OXA-type β-lactamase.[19] It was identified and named as OXA-48. Since 2001 with the appearance of first report on OXA-48, 11 enzyme variants were identified and reported across the world. This includes OXA-48, OXA-48b, OXA-54, OXA-162, OXA-163, OXA-181, OXA-199, OXA-204, OXA-232, OXA-242, and OXA-247. These enzyme variants differ by few amino acid substitution or deletion [Table 2]. OXA-48 and its variants were named and placed under the group as OXA-48-like variants. Most common host

Table 1: Substrate, hydrolysis and inhibitory profile of carbapenemase

| Ambler class | Representative carbapenemase | Hydrolysis profile | Inhibitory profile | Enterobacteriaceae | Nonfermenters |
|--------------|------------------------------|--------------------|--------------------|-------------------|---------------|
| Class A      | KPC                          | −−−−               | ++                 | −−−−              | +++          |
| Class B      | IMP, VIM*                    | ++                 | ++                 | −                 | +++          |
| Class D      | OXA-48-like                  | ++                 | −                  | −                 | ++           |

In particular, OXA-48 hydrolysis cephalosporins and carbapenem poorly and make it difficult for detection under routine laboratory diagnosis. Additionally OXA-48-like variant was not inhibited specifically by the inhibitors in clinical use. *IMP and VIM are integron-associated elements and facilitates its insertion into plasmid. In contrast, KPC, NDM and OXA-48-like are plasmid encoded. EDTA: Ethylenediaminetetraacetic acid, OXA-48: Oxacillinase-48, KPC: Klebsiella pneumoniae carbapenemase
for production of OXA-48-like enzymes is Escherichia coli, K. pneumonia, Enterobacter cloacae, Serratia marcescens, Shewanella xiamensis, Citrobacter freundii, Providencia rettgeri, Klebsiella oxytoca, Enterobacter sakazakii, and A. baumannii.[20]

The kinetic properties of OXA-181, OXA-162, and OXA-204 appear broadly similar to OXA-48 in their hydrolytic profile.[21] OXA-181 is one of the most commonly encountered OXA-48-like variants in different geographic regions. OXA-181 weakly hydrolyses both carbapenem and cephalosporin and differs from OXA-48 at four amino acid substitution. In contrast, OXA-163 effectively hydrolyses cephalosporins (ceftazidime, cefotaxime, and cefepime) and aztreonam.[22] Interestingly, this property of OXA-163 is not detectable with OXA-48. Ideally OXA-163 appears similar to ESBL than carbapenemase in substrate profile. Unlike OXA-48, OXA-232 shows relatively lower hydrolytic activity against carbapenem.[23]

Plasmid as vehicle for spread of oxacillinase-48 like determinants

Initially, blaOXA-48 gene was reported in association with insertion sequence (IS)1999 in the upstream region. Later, blaOXA-48 gene is identified on self-transferrable IncL/M-type plasmid.[24] The transposon Tn1999 is located at the downstream of OXA-48 gene. The blaOXA-48 gene is a part of the transposon Tn1999, made of two copies of IS1999 as shown in Figure 1.[25] The most alarming finding is the transferable operon present in IncL/M-type. This plasmid is associated with high conjugation rate and accounts for rapid transfer and spread across the Gram-negative pathogens.[26]

Further variants of Tn1999 were identified with additional IS. Tn1999.2 contains IS/IR element inserted into the upstream region of IS1999 seen in Figure 1. Similarly, an

![Figure 1: Schematic representation of oxacillinase-48 and its transposons, (a) schematic representation of Tn1999 identified with oxacillinase-48 gene, (b) schematic representation of Tn1999.2 identified with oxacillinase-48 gene, (c) schematic representation of Tn1999.3 identified with oxacillinase-48 gene. Horizontal arrows represent the orientation of gene and their transcription. ∆ indicate the interruption of an element/gene by insertion sequence.]

Table 2: Variants of OXA-48-like enzyme and its deviation

| OXA-48-like variants | NCBI reference sequence: Accession number | Deviation from OXA-48 |
|----------------------|-------------------------------------------|----------------------|
| OXA-54*              | WP_011071128                              | 20 substitution at Phe10Leu, Leu11Val, Ile16Val, Val21Met, Lys23Asn, Asn28Lys, Lys29Pro, Ala33Thr, Thr36Ser, Ser40Ala, Val44Ile, Thr104Ala, Asn110Asp, Glu132Gln, Val153Leu, Ile170Val, Ser171Ala, Gly201Ser, Lys218Gln, and Ser244Ala |
| OXA-162              | ADG27454                                  | Single substitution at Thr223Ala |
| OXA-163              | ADY06444                                  | Single substitution at Ser222Asp and four deletions at Arg214, Ile215, Glu216, and Pro227 |
| OXA-181              | BAP34333                                  | Four substitutions at Thr204Ala, Asn210Asp, Glu268Gln, and Ser271Ala |
| OXA-199              | AFC95894                                  | Three substitutions at His28Tyr, Val44Ala, and Asp154Gly |
| OXA-204              | AJF39128                                  | Two substitutions at Gin98His and Thr99Arg |
| OXA-232‡             | AGD91515                                  | Single substitution at Arg214Ser |
| OXA-244              | YP_00909533                               | Single substitution at Arg214Gly |
| OXA-245              | YP_00909534                               | Single substitution at Glu225Tyr |
| OXA-247†             | YP_00909276                               | Two substitutions at Tyr212Ser and Asp212Asn |

Analysis of amino acid substitution/deletion was done using the reference amino acid sequences of the respective OXA-48 variants deposited in NCBI website (http://www.ncbi.nlm.nih.gov/punmed/). *OXA-54: It differs from OXA-48 by 20 amino acids and constitutes a subgroup of OXA-48-like enzymes, ‡OXA-232: A mutant derivative of OXA-181 and not derived from OXA-48, OXA-247: Two amino acid derivative of OXA-163 and was not originated from OXA-48. OXA: Oxacillinase, NCBI: National Center for Biotechnology Information
IS/R element located at the downstream of \( \text{bla}_{\text{OXA-48}} \) gene is called as Tn1999.3 as shown in Figure 1.[27] The hybrid promoter of combined IS/R/IS1999 element results in 2-fold greater hydrolysis of imipenem. Collectively, the presence of both increases the level of carbapenem resistance than possessing either one of the IS.[28]

Each OXA-48-like variants was identified on the plasmid with different ISs and arrangements. Modification in the genetic arrangements is described for the following enzyme variants such as OXA-181, OXA-204 and OXA-232 respectively. Unlike OXA-48, \( \text{bla}_{\text{OXA-181}} \) gene is inserted at the downstream region of ISE\( \text{cp1} \) and form the transposon Tn2013.[29] The presence of ISE\( \text{cp1} \) facilitates the acquisition of ESBL genes such as CTX-M-15.[30] Co-production of OXA-181 with ESBLs makes the resistance profile broader with reliable detection.[31] However limits the therapeutic option; the \( \text{bla}_{\text{OXA-204}} \) gene is found on the IncA/C plasmid contains the transposon Tn2016 with the ISE\( \text{cp1} \) was reported in \( \text{K. pneumoniae} \) from Tunisia. An additional element IS\( \text{kpn} \)15 inserted at the upstream of ISE\( \text{cp1} \). Hybrid promoter was not identified in IS\( \text{kpn} \)15/ISE\( \text{cp1} \) chimera. The promoter of ISE\( \text{cp1} \) regulates the expression of \( \text{bla}_{\text{OXA-204}} \) gene.[32] IncA/C plasmid possess a wide host range and responsible for acquisition and spread of various \( \beta \)-lactamase genes. The notable among them include \( \text{bla}_{\text{CMY}} \) and \( \text{bla}_{\text{CTX-M}} \) genes.[33] In addition, \( \text{bla}_{\text{NDM-1}} \) and \( \text{bla}_{\text{VIM-4}} \) were also found on the plasmid scaffold.[34,35] Further OXA-232 associates with ISE\( \text{cp1} \) and found on non-conjugative plasmids, resulting in failure of transposase to mobilize \( \text{bla}_{\text{OXA-232}} \) gene either due to deletion or duplication in the upstream region of ISE\( \text{cp1} \).[36]

**Epidemiology**

The true prevalence of OXA-48 is relatively unknown due to the varying level of carbapenemase activity and difficult to detect with phenotypic methods. Outbreak of OXA-48 was reported initially from Turkey, United Kingdom and France.[37-39] Clinical cases of OXA-48 producing Enterobacteriaceae was reported widely from Lebanon, Belgium, United Kingdom, Tunisia, Morocco, Oman and Netherland.[40-46] Currently, Turkey, Middle East countries, and North African countries were considered a major reservoir of OXA-48.[47] Many outbreak and sporadic cases were reported in Turkey.[48,49] The emergence of OXA-48 in hospital and community settings was reported sporadically in Senegal.[50] In Spain, nosocomial outbreak of OXA-48 was reported with co-production of CTX-M-15.[51] Recently, an outbreak of OXA-48-like, being predominantly identified with OXA-48 from Netherland, Belgium and Germany.[52-54]

OXA-181 is the most common OXA-48-like variant reported across India. This includes two multicenter and two single center study reporting OXA-48-like. We reviewed 14 studies on OXA-48-like enzymes which include case reports, nosocomial outbreaks and retrospective studies from France, Italy, Spain, the United States, North America, Argentina, Europe and America, New Zealand, Singapore, Japan, and India [Table 3].

Interestingly, most of the OXA-48-like are reported in \( \text{K. pneumoniae} \). The reviewed literature on OXA-48-like reveals ESBLs were the most common co-producing \( \beta \)-lactamase. Among ESBL, CTX-M-15 seems to be predominantly distributed CTX-M-1 group followed by CTX-M-14 belongs to CTX-M-9 cluster as shown in Table 3. Co-production of OXA-48 was also seen with other carbapenemase including NDM-1 and VIM as shown in Table 3.[60] Next to NDM, OXA-48-like is the frequently reporting carbapenemase across India. Further co-production of OXA-48-like with NDM in countries with poor sanitation is worrisome.

**Clinical implication**

OXA-48 is of great clinical concern due to the difficulty in detection with reduced susceptibility to both carbapenem and broad-spectrum cephalosporin. The mortality remains high in patients infected with OXA-48-like producers. The challenging aspect of OXA-48 is that it may go undetected and classified as susceptible with imipenem and meropenem MIC of \((\leq 1 \mu g/ml)\) as per European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines respectively. Accurate screening for the presence of OXA-48 is not possible with MIC determination alone. This OXA-48 remains as a hidden threat that obscures the laboratory diagnosis and complicates the treatment option. The plasmid that carries OXA-48 serves as a potential vehicle for dissemination of genes among clinical isolates and to the intestinal flora.[70] Currently, the plasmid that carries OXA-48 not often carries other antibiotic resistant genes. However recently co-production of OXA-48 with ESBL are being reported which is the cause for great concern.

In case of ESBL negative OXA-48 positive producers, broad spectrum cephalosporin is considered as potential treatment option except those with OXA-163 a potent hydrolyser of cephalosporin. A neonate infected with OXA-48 producing \( \text{K. pneumoniae} \) was successfully treated with cefotaxime and amikacin from France.[71] A patient with central line infection of OXA-48 producing \( \text{E. coli} \)
was recovered on ceftazidime and non-carbapenem combinational therapy.\textsuperscript{[72]} However, the studies supporting the recommendation of broad spectrum cephalosporin in treating ESBL negative OXA-48 positive producers are limited.

Infection with ESBL positive and OXA-48 positive co-producers provide reliable identification but associates with wider range of resistance and limit the treatment option. Co-production of OXA-48 with CTX-M-15 and NDM serves as a vehicle for noscomial outbreaks as multidrug resistant pathogen as shown in Table 3. A better outcome was observed with triple combination of colistin, aminoglycoside with ceftazidime/cefepime in treating patients infected with OXA-48 producers. Molecular characterization is essential to rule out the presence of OXA-48 producers. Thus serves as an attractive treatment option.

### Table 3: Outbreaks, surveillance and clinical case reports of OXA-48 across the world

| Organism          | Number of isolate included | Source of the isolate | Study type       | Study conducted period | OXA-48 and its variants reported (n) | Co-producers | Geographic region |
|-------------------|---------------------------|-----------------------|------------------|------------------------|-------------------------------------|--------------|-------------------|
| K. pneumoniae     | 58                        | Clinical isolates     | Surveillance     | 2011-2013              | OXA-48 (5)                          | CTX-M-15     | France           |
| K. pneumoniae     | 2                         | Clinical isolate     | Clinical case    | 2011                   | OXA-48 (1)                          | CTX-M-15     | Italy            |
| K. pneumoniae     | 71                        | Clinical isolate     | Outbreak         | 2011                   | OXA-48 (71)                         | CTX-M-15     | Spain            |
| K. pneumoniae     | 3                         | Clinical isolates    | Clinical case    | 2011                   | OXA-232 (1)                         | NDM-1        | United States    |
| K. pneumoniae     | 1                         | Clinical isolates    | Clinical case    | 2011                   | OXA-181 (3)                         | CTX-M-15     | North America    |
| K. pneumoniae     | 110                       | Inta-abdominal infections | Surveillance | 2008-2009              | OXA-48 (6)                          | CTX-M-15     | Argentina        |
| K. pneumoniae     | 2                         | Clinical isolates    | Clinical case    | 2008                   | OXA-163 (1)                         | VIM-5        | Asia             |
| E. coli, K. pneumonia | 15,948                  | Clinical isolates    | Surveillance     | 2007-2009              | OXA-48 (58)                         | CTX-M-15     | Europe and America |
| K. pneumoniae     | 1                         | Clinical isolate     | Clinical case    | 2010                   | OXA-181 (1)                         | CTX-M-15     | Newzealand       |
| Enterobacteriaceae| 96                        | Clinical isolates    | Surveillance     | 2010-2012              | OXA-181 (8)                         | CTX-M-15     | Singapore        |
| K. pneumoniae     | 1                         | Clinical isolate     | Clinical case    | 2010                   | OXA-181 (1)                         | CTX-M-15     | Japan            |
| Enterobacteriaceae| 1443 (26-CRE)             | Clinical isolates    | Multicenter SENTRY surveillance program | 2006-2007 | OXA-181 (10) | CTX-M-15 (10) VIM-5 (1) | Argentina |
| Enterobacteriaceae| 235 (66-CRE)              | Clinical isolate     | SMART study      | 2009                   | OXA-48 (3)                          | CTX-M-15     | Asia             |
| Enterobacteriaceae| 111                       | Clinical isolate     | Single center    | 2010                   | OXA-181 (2)                         | Reported in K. pneumoniae and C. freundii | Asia       |
| E. coli           | 300                       | Clinical isolate     | Single center    | 2012                   | OXA-48 (25)                         | NDM-1        | Only E. coli included in the study | Asia       |

\textsuperscript{E. coli: Escherichia coli, K. pneumonia: Klebsiella pneumoniae, C. freundii: Citrobacter freundii, OXA: Oxacillinase}

In an in-vivo study, an infection is induced in murine model with OXA-48 producing K. pneumoniae.\textsuperscript{[77]} The strains were susceptible to ceftazidime and imipenem as per MIC. However, the outcome was better with ceftazidime than with carbapenem treated group. A similar result was also revealed in experimental mice, in which peritonitis was induced with ESBL negative and OXA-48 producing K. pneumoniae.\textsuperscript{[78]} Further clinical profile of OXA-48 producers does not concur with carbapenem MIC breakpoints ≤1 μg/ml (i.e., ≤1 μg/ml can be OXA-48 producers). Irrespective of carbapenem susceptibility, carbapenem is not reliable in treating patients infected with OXA-48 producers.

The optimal treatment remains unclear. In vitro susceptibility to colistin, tigecycline and aminoglycosides were promising.\textsuperscript{[79,80]} However, there is a limited proven clinical efficacy. Notably, emerging resistance to this antibiotic is already reported.\textsuperscript{[81,82]} Some studies have reported the better outcome with combinational therapy rather than with monotherapy.\textsuperscript{[83]}

Avibactam, a non-β lactam β lactamase inhibitor selectively inhibits Class D OXA-48, Class A and Class C β-lactamase. It forms a stable complex with OXA-48 by establishing covalent bond.\textsuperscript{[73]} The combination of avibactam with imipenem and cephalosporin (cefepeime, ceftazidime, and cefotaxime) significantly reduces the MIC value of OXA-48 producers.\textsuperscript{[76]} Interestingly, avibactam was identified with the broad coverage of OXA and other β-lactamase. Thus serves as an attractive treatment option.

Appropriate therapy for OXA-48 is unpredictable and presents with multidrug resistant profile. Carbapenem MIC alone is not enough for treating patients with OXA-48 producers. Molecular characterization is essential to rule out the presence of OXA-48 producers that shows heterogeneous hydrolytic profile in phenotypic detection (MIC). Screening for OXA-48 in patient is necessary to prevent the noscomial outbreak prior to hospital admission. Rectal screening of the patient offers detection at the earliest and initiation of appropriate therapy.\textsuperscript{[84]}

---

Devi, et al.: OXA-48 like and its difficulty in laboratory detection
Laboratory detection of oxacillinase-48

Carbapenemase production is identified with the reduction in susceptibility to carbapenem. However, OXA-48-like exhibits low carbapenemase activity and makes it difficult to detect. At present, an OXA-48-like producer is not detectable with the well-defined phenotypic methods using β-lactam and β-lactamase inhibitor combination used to detect Class A and Class B carbapenemase. Further, a good inhibitor is not available for specific analysis of OXA-48-like enzyme. The most challenging part of OXA-48 detection is that it differs from other carbapenemase by exhibiting susceptibility to broad spectrum cephalosporins but remains resistant to carbapenem. However, the marker is not consistent to selectively identify OXA-48 as some may show resistance to both broad-spectrum cephalosporins and carbapenem equally. Most of the studies on carbapenemase detection are focused on Class A and Class B-metallo-β-lactamase. Very few studies are carried out for OXA-48-like detection.

Carbapenem minimum inhibitory concentrations and interpretative criteria

Resistance to carbapenem is reported on the basis of susceptibility testing. According to the CLSI guidelines (M100-S25), MIC breakpoints for imipenem and meropenem are susceptible (≤1 μg/ml) and resistant (>4 μg/ml). For ertapenem, the breakpoints are susceptible (≤0.5 μg/ml) and resistant (>2 μg/ml). The role of ertapenem with low MIC breakpoint in detecting OXA-48 remains to be assessed.

Modified Hodge test

Modified Hodge Test (MHT) or cloverleaf technique recommended by CLSI guidelines (M100-S25) is used extensively as a nonspecific screening test for routine diagnosis of carbapenemase producers. Carbapenemase producers inactivate the carbapenem and promote the growth of carbapenem susceptible indicator strain along the streak line toward carbapenem disk and results in a characteristic cloverleaf-like indentation. Comparable sensitivity but poor specificity was observed with MHT of 98% and 80% respectively with the longer turnaround time.[85] For OXA-48, MHT is found to be better with sensitivity and specificity of 96% and 84% respectively (unpublished data) contrast to the percentage described in CLSI. This may be due to the variation in the prevalence of OXA-48-like enzymes in different geographic regions. False negative results account for lack of specificity and low sensitivity. Unlike NDM, detection of OXA-48 seems to be better with MHT.[86]

Temocillin and minimum inhibitory concentrations

Temocillin, a semi synthetic β-lactam is identified as a suggestive marker to screen OXA-48-like determinants that confers high-level resistance.[87] Temocillin is stable against the hydrolysis of ESBL and AmpC enzymes.[88] However, high level of temocillin resistance is not only the characteristics of OXA-48-like producers but similar level of resistance is also observed with KPC and metallo-β-lactamase. Hence temocillin alone is not a diagnostic marker for OXA-48-like detection.[89] Temocillin with high-level MIC and nonsusceptibility to ceftriaxone and other third generation cephalosporin gives the clue for the presence of OXA-48-like enzymes. Nonavailability of temocillin in many countries makes it impossible for screening. In CLSI or EUCAST guidelines breakpoint for temocillin is not available. Temocillin breakpoints are established by the British Society for Antimicrobial Therapy (BSAC), and it is the only available guideline to define temocillin MIC breakpoints as well zone diameter for interpretation of strains. According to BSAC, the breakpoints for temocillin are susceptible (≤32 μg/ml) and resistant (>32 μg/ml), and the zone diameter of ≥12 mm and ≤11 mm are defined as susceptible and resistant, respectively.[90]

Disc diffusion assay

Disc diffusion assay using temocillin, meropenem, BA, and/or DPA which is commercially available as KPC/MBL and OXA-48 Confirm Kit (Rosco Diagnostics) is used to discriminate OXA-48-like enzymes from other carbapenemase. If the synergy is not observed with meropenem and phenyl BA and/or DPA and temocillin with the zone diameter of <10 mm is identified as OXA-48 producers with the sensitivity and specificity of 100%.[91] Mastdiscs ID inhibitor combination disks are also useful for presumptive detection of OXA-48.

Chromogenic medium

Chromogenic medium enables rapid identification of carbapenem resistant pathogens either from clinical samples or from isolates. Although chromogenic media are a fairly rapid means of detecting CRO, its use is confined to rectal swab. Chrom ID OXA-48 is the only available chromogenic medium for selective identification of OXA-48 [Table 4]. Its exact composition is undisclosed; however, the media contains antibiotic for the inhibition of other microorganism and biochemical
markers to differentiate species or groups of species using either chromogenic substrates or fermentable carbohydrates with a pH indicator. The sensitivity of chromogenic medium can be increased by incubating the plates for complete 24 h. In contrast to manufacturer’s claims, false positives can occur. Confirmation of all positives with either disc diffusion assay or by molecular characterization is recommended.

**Rapid diagnosis**

Accurate and earlier detection of OXA-48-like determinants is necessary for better management of patient and infection control. The following rapid diagnostic methods tests are available for detection of carbapenemase producers.

**Carba NP**

Carba NP is a hydrolytic assay recommended by CLSI (M100-S25) guidelines as a confirmatory test for detection of carbapenemase that is simple and easy to perform. Hydrolysis of imipenem is indicated by the change in the pH of indicator phenol red and the color changes from red to yellow with the turnaround time <2 h. It has a sensitivity and specificity of 100% in detecting Class A and Class B metallo-β-lactamase.[93] However, the sensitivity of calorimetric microtube assay/Carba NP is shown to be 11% with OXA-48 according to CLSI guidelines (CLSI-2015). While in our experience we observed, Carba NP for OXA-48 detection shows sensitivity and specificity of 77% and 84% respectively (unpublished data). Indeed, suspected cause for low sensitivity with OXA-48-like enzymes is due to the presence of mucoid strains and/or weak carbapenemase activity. Further sensitivity of Carba NP with mucoid phenotypes may be improved by extending the incubation period from ½ to 1 h and reduction of inoculum size was preferred.[94] For weak carbapenemase producers, concentrated extract of cell suspension was recommended.[97]

Blue Carba is a variant of Carba NP in which bromothymol blue is used as an indicator instead of phenol red as in Carba NP assay. The main advantage of Blue Carba over Carba NP is the direct colony suspension approach without the need for lysis buffer.[98] The sensitivity and specificity of Blue Carba in detecting OXA-48 is yet to be established.

**Molecular based techniques**

Phenotypic test identifies the carbapenemase producers in general without any specification over the class of carbapenemase. Molecular characterization is the only available tool for discriminating different carbapenemase encoding genes. Polymerase chain reaction (PCR) is considered as the gold standard for identification of OXA-48 and it should be followed by sequencing for the precise identification of enzyme variants of OXA-48-like. In addition to the conventional PCR, real-time PCR and microarray designed panels are also available for rapid detection of OXA-48-like [Table 5].[99-102] Matrix-assisted laser desorption ionization time-of-flight mass spectrometry is evaluated and available for detection of OXA-48, although its use in routine diagnosis is restricted due to the cost.

**Xpert® Carba-R**

Xpert® Carba-R is developed on the basis of real time PCR and the results are available with the turnaround time of 2 h. The panel of Xpert® Carba-R contains the sequences for targeting bla_{IMP}, bla_{VIM}, bla_{NDM}, bla_{KPC}, and bla_{OXA-48} genes. Of the 11 known variants of OXA-48-like, only four variants (bla_{OXA-48}, bla_{OXA-163}, bla_{OXA-162}, and bla_{OXA-28}) were designed to detect.[103] Incorporation of geographic-specific OXA-48-like variants in the proprietary panel may improve its sensitivity and broadens the detection of OXA-48-like enzymes across the world.

The Class A (KPC) and Class B (IMP, VIM, NDM) is considered important carbapenemases with focus of high priority. However, recently Class D carbapenemase OXA-48 is rapidly emerging and disseminating in Gram-negative pathogens. Interestingly, the self-conjugative plasmids that carry bla_{OXA-48} gene in composite transposons

---

Table 4: Comparison of chromogenic medium for the detection of carbapenem resistant organism

| Chromogenic medium                  | Available          | Number of isolates screened | Sensitivity (%) | Specificity (%) | Remarks                                                                 |
|-------------------------------------|--------------------|-----------------------------|-----------------|-----------------|--------------------------------------------------------------------------|
| Brilliant CRE agar*B<sup>[41]</sup> | Oxoid, ThermoFisher Scientific | 255                         | 94              | 71              | Sensitivity is lower with OXA-48 (84%) than with KPC, NDM (100%)         |
| Chrom ID CARBA<sup>[92]</sup>       | Biomerieux         | 133                         | 92.4            | 96.9            | OXA-48 detected at high inoculum of 10<sup>7</sup> CFU/ml               |
| Chrom ID OXA-48 and SUPERCARBA<sup>[93]</sup> | Biomerieux         | 117                         | 91              | 100             | Validated only for OXA-48 detection                                     |

*Brilliant CRE agar was found to be less optimal in detecting OXA-48-like. The specificity was low due to the growth of AmpC- and/or ESBL-producing isolates. OXA-48: Oxacillinase-48
Although Tn1999 account for rapid spread as a single clone. As a consequence of low carbapenemase activity and poor hydrolyzes of broad spectrum cephalosporins complicates the identification. As a result, silent spread and outbreak occurs. Further surveillance studies are necessary to understand the dynamic of transmission, risk factors and reservoir of OXA-48 producers.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Perez F, Van Duin D. Carbapenem-resistant Enterobacteriaceae: A menace to our most vulnerable patients. Cleve Clin J Med 2015;80:225-33.
2. Temkin E, Adler A, Lerner A, Carmeli Y. Carbapenem-resistant Enterobacteriaceae: Biology, epidemiology, and management. Ann N Y Acad Sci 2014;1323:22-42.
3. Miriagou V, Cornaglia G, Edelstein M, Galani I, Giske CG, Gniadkowski M, et al. Acquired carbapenemases in Gram-negative bacterial pathogens: Detection and surveillance issues. Clin Microbiol Infect 2010;16:112-22.
4. Poirel I, Pitout JD, Nordmann P. Carbapenemases: Molecular diversity and clinical consequences. Future Microbiol 2007;2:501-12.
5. Antunes NT, Lamoureaux TL, Toth M, Stewart NK, Frase H, Vakulenko SB. Class D β-lactamases: Are they all carbapenemases? Antimicrob Agents Chemother 2014;58:2119-25.
6. Potron A, Poirel L, Rondinaud E, Nordmann P. Intercontinental spread of OXA-48 beta-lactamase-producing Enterobacteriaceae over a 11-year period, 2001 to 2011. Euro Surveill 2013;18. pii: 20549.
7. Poirel I, Naas T, Nordmann P. Diversity, epidemiology, and genetics of class D beta-lactamases. Antimicrob Agents Chemother 2010;54:24-38.
8. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: Here is the storm! Trends Mol Med 2012;18:263-72.
9. Queenan AM, Bush K. Carbapenemases: The versatile beta-lactamases. Clin Microbiol Rev 2007;20:440-58.
10. Göttig S, Gruber TM, Stecher B, Wielchel TA, Kempf VA. In vivo horizontal gene transfer of the carbapenemase OXA-48 during a nosocomial outbreak. Clin Infect Dis 2015;60:1808-15.
11. Hrabák J, Chudácková E, Papagiannitsis CC. Detection of carbapenemases in Enterobacteriaceae: A challenge for diagnostic microbiological laboratories. Clin Microbiol Infect 2014;20:839-53.
12. Djahmi N, Dnyach-Remy C, Pantel A, Dekhil M, Sotto A, Lavigne JP. Epidemiology of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean countries. Biomed Res Int 2014;2014:305784.
13. Nordmann P, Gniadkowski M, Giske CG, Nordmann P, et al. Carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 2012;18:432-8.
14. Mathlouthi N, Areiz Z, Al Baysari C, Balour S, et al. Emergence of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii clinical isolates collected from some Libyan hospitals. Microb Drug Resist 2015;21:335-41.
15. Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 2010;23:160-201.
16. Docquier JD, Calderone V, De Luca F, Benvenuti M, Giuliani F, Bellucci L, et al. Crystal structure of the OXA-48 beta-lactamase reveals mechanistic diversity among class D carbapenemases. Chem Biol 2009;16:540-7.
17. Potron A, Kalpoe J, Poirel L, Nordmann P. European dissemination of a single OXA-48-producing Klebsiella pneumoniae clone. Clin Microbiol Infect 2011;17:E24-6.
18. Nordmann P, Naas T, Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17:1791-8.
19. Poirel L, Hérutier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004;48:15-22.
20. Evans BA, Amyes SG. OXA-β-lactamases. Clin Microbiol Rev 2014;27:241-63.
21. Oueslati S, Nordmann P, Poirel L. Heterogeneous hydrolytic features for OXA-48-like β-lactamases. J Antimicrob Chemother 2015;70:1059-63.
22. Abdelaziz MO, Bonura C, Aleo A, El-Domany RA, Fasciana T, Mammina C, et al. Emergence of clinical Klebsiella pneumoniae producing OXA-232 carbapenemase in Singapore. New Microbes New Infect 2013;1:13-5.
23. Berger S, Alauzet C, Aissa N, Hénard S, Rabaud C, Bonnet R, et al. Characterization of a new blaOXA-48 carrying plasmid in Enterobacteriaceae. Antimicrob Agents Chemother 2013;57:4064-7.
24. Aubert D, Naas T, Hérutier C, Poirel L, Nordmann P. Functional characterization of IS1999, an IS4 family element involved in mobilization and expression of beta-lactam resistance genes. J Bacteriol 2006;188:6506-14.
73. Balkan II, Aygün G, Aydin S, Mutcali SI, Kara Z, Kuskucu M, Shanthi M, Sekar U, K A, Bramhne HG. OXA-181 Beta Lactamase is not a Major Mediator of Carbapenem Resistance in Enterobacteriaceae. J Clin Diag Res 2013;7:1986-8.

74. Shibli A, Al-Agamy M, Memish Z, Senok A, Khader SA, Assiri A. The emergence of OXA-48 and NDM-1-positive Klebsiella pneumoniae in Riyadh, Saudi Arabia. Int J Infect Dis 2013;17:e1130-3.

75. Nordmann P, Poirel L. Strategies for identification of carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 2013;68:487-9.

76. Levast M, Poirel I, Carrér A, Deiber M, Deeroissette E, Mallaval FO, et al. Transfer of OXA-48-positive carbapenem-resistant K. pneumoniae from Turkey to France. J Antimicrob Chemother 2011;66:944-5.

77. Goren MG, Chmelinskiy I, Carmeli Y, Navon-Venezia S. Plasmid-encoded OXA-48 carbapenemase in Escherichia coli from Israel. J Antimicrob Chemother 2011;66:672-3.

78. Mimoz O, Grégoire N, Poirel L, Marliat M, Couet W, Nordmann P. Broad-spectrum β-lactamase inhibitor. Proc Natl Acad Sci U S A 2012;109:11663-8.

79. Aktaş Z, Kayacan C, Oncul O. In vitro activity of aβ-lactamase inhibitor. Proe Natl Acad Sci U S A 2012;109:11663-8.

80. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant K. pneumoniae. Int J Infect Dis 2014;22:51-6.

81. Yamamoto M, Pop-Vicas AE. Treatment for infections with carbapenem-resistant Enterobacteriaceae: What options do we still have? Crit Care 2014;18:229.

82. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Kern G, et al. Abiabactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci U S A 2012;109:11663-8.

83. Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. Evaluation of the Oxoid Brilliance™ CRE Agar for the detection of carbapenemase-producing Enterobacteriaceae. J Clin Microbiol 2011;49:2857-61.

84. Liverton DM, Warner M, Mushatq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and ticigycline. Int J Antimicrob Agents 2011;37:415-9.

85. Zarkotou O, Pourmaras S, Voulgaris F, Chrysos G, Prekates A, Voutsinas D, et al. Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: A matched case-control study. J Clin Microbiol 2010;48:2271-4.

86. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections due to OXA-48-producing K. pneumoniae. J Infect Dis 2010;202:2271-4.

87. Dortet L, Anglade C, Zambardi G, Nordmann P. Comparative evaluation of a novel chromogenic medium (chromID K. pneumoniae) for detection of carbapenemase-producing Enterobacteriaceae in surveillance rectal swabs. J Antimicrob Chemother 2012;65:1999-2004.

88. Girlich D, Glupczynski Y, Nordmann P. Evaluation of a commercial multiplex PCR. J Clin Microbiol 2012;50:4371-4.

89. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. In vitro activity of avibactam (NXL104). Int J Antimicrob Agents 2012;39:86-9.

90. Naas T, Cuzon G, Bogaerts P, Glupczynski Y, Nordmann P. Evaluation of a novel chromogenic medium. J Antimicrob Chemother 2013;68:487-9.

91. Sauget M, Cabrolier N, Manzoni M, Bertrand X, Hocquet D. Rapid, sensitive and specific detection of OXA-48-like-producing Enterobacteriaceae by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Microbiol Methods 2014;105:89-91.

92. Lafeuille E, Louira S, Sougakoff W, Soulier-Estehnoua O, Leconte J, Garee H, et al. Detection of OXA-48-like carbapenemase genes by the Xpert® Carba-R test: Room for improvement. Int J Antimicrob Agents 2015;45:441-2.